Infectious Disease Advisor news story
Switching to a once-daily bictegravir/lenacapavir (BIC/LEN) single-tablet regimen is generally well tolerated through 48 weeks among people with HIV (PWH) and comorbid dyslipidemia, hypertension, or diabetes. These study results were presented at IDWeek 2026, held from October 21 to 24, in Washington, DC.
Researchers evaluated safety outcomes from the phase 3 portion of ARTISTRY-1 (ClinicalTrials.gov Identifier: NCT05502341), a randomized, open-label trial involving PWH who had achieved virologic suppression while receiving complex antiretroviral therapy regimens. Participants were randomly assigned 2:1 to switch to once-daily BIC/LEN or continue their existing regimens.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
View all Infectious Disease Advisor reports from IDWeek 2026
SEE ALSO:
- [IDWeek 2026] Contagion Live | Bictegravir/lenacapavir well tolerated in HIV with comorbidities
View all Contagion Live reports from IDWeek 2026
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
-
[IDWeek 2026] Contagion Live | Asuptegravir lowers HIV-1 RNA up to 2.36 logs in early monotherapy
-
[IDWeek 2026] Infectious Disease Advisor | Novel doravirine/islatravir yields similar patient-reported outcomes in HIV-1
-
[IDWeek 2026] Infectious Disease Advisor | Recombinant zoster vaccination reduces cardiovascular risks in HIV
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.